Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.
Pleyer L, Heibl S, Tinchon C, Vallet S, Schreder M, Melchardt T, Stute N, Föhrenbach Quiroz KT, Leisch M, Egle A, Scagnetti L, Wolf D, Beswick R, Drost M, Larcher-Senn J, Grochtdreis T, Vaisband M, Hasenauer J, Zaborsky N, Greil R, Stauder R. Pleyer L, et al. Among authors: stauder r. Cancers (Basel). 2023 Feb 22;15(5):1388. doi: 10.3390/cancers15051388. Cancers (Basel). 2023. PMID: 36900181 Free PMC article.
Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.
Rochau U, Stojkov I, Conrads-Frank A, Borba HH, Koinig KA, Arvandi M, van Marrewijk C, Garelius H, Germing U, Symeonidis A, Sanz GF, Fenaux P, de Witte T, Efficace F, Siebert U, Stauder R. Rochau U, et al. Among authors: stauder r. Br J Haematol. 2020 Nov;191(3):405-417. doi: 10.1111/bjh.16654. Epub 2020 May 14. Br J Haematol. 2020. PMID: 32410281 Free PMC article.
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.
Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J. Braulke F, et al. Among authors: stauder r. Genes Chromosomes Cancer. 2015 Dec;54(12):809-17. doi: 10.1002/gcc.22292. Epub 2015 Sep 10. Genes Chromosomes Cancer. 2015. PMID: 26355708
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Greenberg PL, et al. Among authors: stauder r. Blood. 2016 Oct 20;128(16):2096-2097. doi: 10.1182/blood-2016-07-728766. Epub 2016 Aug 17. Blood. 2016. PMID: 27535995 Free PMC article. No abstract available.
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E. Schanz J, et al. Among authors: stauder r. J Clin Oncol. 2011 May 20;29(15):1963-70. doi: 10.1200/JCO.2010.28.3978. Epub 2011 Apr 25. J Clin Oncol. 2011. PMID: 21519021 Free PMC article.
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective.
De Witte T, Malcovati L, Fenaux P, Bowen D, Symeonidis A, Mittelman M, Stauder R, Sanz G, Čermák J, Langemeijer S, Hellström-Lindberg E, Germing U, Skov Holm M, Mądry K, Tatic A, Medina Almeida A, Savic A, Mandac Rogulj I, Itzykson R, Hoeks M, Gravdahl Garelius H, Culligan D, Kotsianidis I, Ades L, Van de Loosdrecht AA, Van Marrewijk C, Yu G, Crouch S, Smith A. De Witte T, et al. Among authors: stauder r. Haematologica. 2020 Nov 1;105(11):2516-2523. doi: 10.3324/haematol.2020.266817. Haematologica. 2020. PMID: 33054132 Free PMC article. No abstract available.
The EHA Research Roadmap: Anemias.
Iolascon A, Rivella S, Anagnou NP, Camaschella C, Swinkels D, Muckenthaler MU, Porto G, Barcellini W, Andolfo I, Risitano AM, Kattamis A, Cappellini MD, Taher AT, De Franceschi L, Rees D, Russo R, Tamary H, Stauder R, Girelli D. Iolascon A, et al. Among authors: stauder r. Hemasphere. 2021 Jun 30;5(7):e607. doi: 10.1097/HS9.0000000000000607. eCollection 2021 Jul. Hemasphere. 2021. PMID: 34522846 Free PMC article. No abstract available.
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.
Amadori S, Suciu S, Willemze R, Mandelli F, Selleslag D, Stauder R, Ho A, Denzlinger C, Leone G, Fabris P, Muus P, Vignetti M, Hagemeijer A, Beeldens F, Anak O, De Witte T; EORTC leukemia group; GIMEMA leukemia group. Amadori S, et al. Among authors: stauder r. Haematologica. 2004 Aug;89(8):950-6. Haematologica. 2004. PMID: 15339678 Clinical Trial.
172 results